SAN DIEGO—(BUSINESS WIRE)—Nov. 3, 2008—ACADIA PharmaceuticalsInc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will present at The Rodman & Renshaw 10th Annual HealthcareConference on Tuesday, November 11, 2008, at 11:35 a.m. Eastern Timeat The New York Palace Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible on thecompany's website, www.acadia-pharm.com, under the investors sectionand an archived recording will be available on the website throughNovember 25, 2008.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA is focused ondeveloping a portfolio of its four most advanced product candidates,including pimavanserin in Phase III for Parkinson's disease psychosis,a compound in Phase II for chronic pain and a compound in Phase I forglaucoma, both in collaboration with Allergan, and ACP-106 inIND-track development. All of the product candidates in ACADIA'spipeline emanate from discoveries made using its proprietary drugdiscovery platform and are directed at indications with large unmetmedical needs. ACADIA's corporate headquarters is located in SanDiego, California and it maintains research and development operationsin both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President andChief Financial Officer
858-558-2871
SOURCE: ACADIA Pharmaceuticals Inc.